Clinical Study Assessing a New Scale to Measure Onset of Action in Generalized Anxiety Disorder
Public ClinicalTrials.gov record NCT00715039. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A 4-Week, Double-Blind, Randomized, Multicenter, Fixed Dose, Placebo-Controlled, Parallel Group Study of Lorazepam and Paroxetine in Patients With Generalized Anxiety Disorder: Assessment of a New Instrument Intended to Capture Rapid Onset
Study identification
- NCT ID
- NCT00715039
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Not applicable
- Lead sponsor
- Pfizer
- Industry
- Enrollment
- 169 participants
Conditions and interventions
Conditions
Interventions
- lorazepam Drug
- placebo Drug
- paroxetine Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 65 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 30, 2003
- Primary completion
- Not listed
- Completion
- Apr 30, 2004
- Last update posted
- Oct 2, 2008
2003 – 2004
United States locations
- U.S. sites
- 15
- U.S. states
- 6
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Pfizer Investigational Site | Glendale | California | 91206 | — |
| Pfizer Investigational Site | Northridge | California | 91406 | — |
| Pfizer Investigational Site | Orange | California | 92868 | — |
| Pfizer Investigational Site | San Diego | California | 92105 | — |
| Pfizer Investigational Site | Sherman Oaks | California | 91403 | — |
| Pfizer Investigational Site | Van Nuys | California | 91406 | — |
| Pfizer Investigational Site | Casselberry | Florida | 32707 | — |
| Pfizer Investigational Site | Orlando | Florida | 32806 | — |
| Pfizer Investigational Site | Atlanta | Georgia | 30328 | — |
| Pfizer Investigational Site | Marietta | Georgia | 30060 | — |
| Pfizer Investigational Site | Overland Park | Kansas | 66209 | — |
| Pfizer Investigational Site | Overland Park | Kansas | 66211 | — |
| Pfizer Investigational Site | Albuquerque | New Mexico | 87102 | — |
| Pfizer Investigational Site | Albuquerque | New Mexico | 87104 | — |
| Pfizer Investigational Site | Cincinnati | Ohio | 45267-0559 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00715039, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 2, 2008 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00715039 live on ClinicalTrials.gov.